Hi resourced,"Someone needs to make up their mind whether this...

Hi resourced,

"Someone needs to make up their mind whether this is QUT technology, the Co-op Research Centre's or Tissue Therapies' because all these QUT press releases in recent times hardly even mention TIS"

I've been waiting for someone to raise this question for sometime now...

Not to be misunderstood, as I believe TIS holders have nothing to be concerned about in regards to its long term licensing arrangements with QUT, however new innovative technology developments today often demand a multidisciplinary approach to problem solving along the development pathway, and in doing so will often require a collaborative effort involving experts in the field across a number of different scientific disciplines in R&D.

We must also come to understand that collaborations in R&D will also require the sharing of IP and trade secrets, and as a result of this, Non-disclosure or confidentiality agreements facilitated between parties make up an important part of the new product innovation landscape.

I am currently heavily invested in a $18m Mkt Cap company which has progressed its technology platforms across a variety of different industry sectors with some of the world's largest companies in the field of Pharmaceutical, Healthcare, Home Care, Cosmetic and industrial applications. All but one of the major expenditure required for all of its development programs are currently being partner funded, and as a result of this and the confidentiality agreements the market have been receiving much less information than even the s/holders of Tissue Therapies have been afforded over recent years.

As a result of my own exhaustive research into the small company I am invested I know that much of the impressive R&D activity in the area of Wound Care Management announced to the market has all but vanished since just before receiving an invite to present their work at the 8th World Congress on Inflammation held at the Copenhagen Conference Center in Denmark on June 16-20 in 2007. All information relating to that invite, and the four seperate Poster Presentations delivered at that event were omitted from market announcements, and to this day have still received no mention.

I know that in 2008 the company I am invested commenced a new collaboration with the Australian Research Council (ARC) which involved funding research at the University of Queensland, specifically where the initial programs were being led by a Prof Michael Roberts, under the title, "Topical peptide delivery for cosmetic and therapeutic benefits"

Prof Michael Roberts is the Director of the Therapeutics Research Centre at the University of Queensland. He is also an Australian National Health & Medical Research Council Senior Principal Research Fellow based at the School of Medicine at Princess Alexandra Hospital in Brisbane, Australia. His research interests are in experimental and clinical therapeutics and in pharmaceutical science.

I understand that Tissue Therapies commercial business partner is the Queensland University of Technology, home to your Prof Upton, and I appreciate that there would be very few connections made between Prof Roberts and Prof Upton, other than perhaps, the University of Queensland's Burns Trauma and Critical Care Research Centre as cited in this Burns, Trauma & Critical Care Research Centre report, for example, however this can also be the joy of researching where confidentiality provisions may apply.

I also know that at the "Conjoint Australasian Wound and Tissue Repair Society (AWTRS) and Australasian Society for Dermatology Research (ASDR) Conference" held in Sydney on May 24 of which one of my company's collaborating scientists is the President and another one of my company's collaborating scientists from the University of Queensland presented to the "Emerging Technologies / Biomaterials" symposia only one hour before Tissue Therapies collaborating scientist, Prof Upton took to the stage to address the "Wound Management Innovation CRC" symposia.

At this point I should confirm that to the best of my knowledge no direct connections can be made between the company I an invested and TIS, Prof Upton, Prof Keith Harding, VitroGro or the Cardiff University in the UK, however I do wish to put one question to yourself or any other TIS holder here who may be able to enlighten me with a plausible answer to the following:

When opening the Tissue Therapies - Home Page of your new website the following is cited at the foot of the page:

[1] Vowden P. Hard to heal wounds made easy. Wounds International 2011
[3] Vowden KR. and Vowden P. The prevalence, management, equipment provision and outcomes for patients with pressure ulceration identified in a wound care survey with one English health care district. J. Tissue Viability 2009.

Question: What relationship does Prof. Peter Vowden have with Tissue Therapies?

The reason for this question is that I know Prof. Vowden doesn't conduct research at QUT or Cardiff University. He is the Professor of Wound Healing Research for Bradford Teaching Hospitals NHS Foundation Trust at the University of Bradford in the UK - and importantly, the published work cited in the first reference on Tissue Therapies website was supported by an educational grant from TEVA UK Ltd. - Source: Wounds International - Volume 2 Issue 4 - November 2011

The company to which I am invested have a very strong collaborative relationship with the University of Bradford in the UK through the Research & Knowledge Transfer Support network, and although no intimate details of this collaboration have been announced to the market, citings can be found by those who choose to research - Like page 3 of this Bradford newsletter as one example, which states:

Collaborative and RKT Centre Successes
"Steve Britland, Centre for Skin Sciences, has attracted international research funding to the value of £33,000 in a collaborative development with *** of Australia for the development of innovative bioequivalence models for use in specialised areas of transdermal drug delivery research."

Prof Britland is the Team Leader in Clinical Therapeutics in the Centre for Skin Science at the University of Bradford. He is an expert in chronic wound management and lists the current projects he is working on as:
* Novel device for wound healing comprising a biodegradable polymer micro-particle containing stem cells
* Industrial contract in trans-cutaneous drug delivery

Now refering back to Tissue Therapies website citing of Prof Peter Vowden, here are the last two published research papers citing his name:

2012 May 11
The lactate conundrum in wound healing: Clinical and experimental findings indicate the requirement for a rapid point-of-care diagnostic.
Britland S, Ross-Smith O, Jamil H, Smith AG, Vowden K, Vowden P.
Centre for Skin Sciences and School of Pharmacy, University of Bradford, Bradford BD7 1DP, U.K.. [email protected].
The lactate conundrum in wound healing: Clinical and experimental findings indicate the requirement for a rapid point-of-care diagnostic

2011 May-Jun;27
Recombinant Lucilia sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo.
Britland S, Smith A, Finter W, Eagland D, Vowden K, Vowden P, Telford G, Brown A, Pritchard D.
School of Pharmacy and Centre for Skin Sciences, University of Bradford, Bradford BD7 1DP, UK. [email protected]
Recombinant Lucilia sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo.

In closing if we once again refer back to the particular presentation by Prof Vowden as cited on Tissue Therapies website, and as previously noted in this post, funded by TEVA UK Ltd

Whilst I can confirm that the company to which I am invested does not have any direct connection with Teva, they do have a direct connection with the world's largest consumer goods company, P&G, so if I could draw your attention to the recently announced formation of a new company aptly named, PGT Healthcare - A new Joint Venture between Procter and Gamble and Teva, and the following letter dated November 03, 2011 which was forwarded to all of P&G's business partners from P&G's Chief Purchasing Officer:

Could this by any chance at all have anything to do with the referenced, CE Marking delays...?

To Our Valued External Business Partners:
P&G and Teva Pharmaceuticals have completed their deal to form a partnership in consumer health care. The companies are creating a new business model by bringing together both companies’ over-the counter (OTC) products and complementary capabilities to accelerate growth. The companies are in process of completing a joint global sourcing study to determine the best scenario for the supply of all of the remaining OTC business and the structure of all remaining Product Supply capabilities. We ask for your utmost support to make this partnership a success for all of us. There are many details to be worked out over the coming months on how the JV will affect the materials and services supplied for these OTC products. We will communicate additional updates as soon as it is practical to do so. - To Our Valued External Business Partners: 03 November 2011

The Procter & Gamble Company and Teva Pharmaceutical Industries Announce Formation of New Consumer Health Care Partnership
New Joint Venture, to be named “PGT Healthcare,” has the potential to reach double-digit sales growth and $4 billion in sales towards end-of-decade. - The Procter & Gamble Company and Teva Pharmaceutical Industries Announce Formation of New Consumer Health Care Partnership

P&G's Masterstroke: The Teva Deal
November 20, 2011 by Donald Riker, PhD
P&G and Teva Pharma formed a strategic healthcare joint venture on Nov 3, 2011. In one masterstroke P&G has created synergies in multiple dimensions and has forged a new business model that should be the envy of the consumer healthcare industry. This strategic vision of complementary global competencies far outdistances the piecework roll up model and the serial one-off acquisitions we are so use to seeing. This deal is unlike any deal in consumer healthcare before it. - OTC Product News - 20/11/2011

Just in case you forgot the purpose of this post, i'll ask the question again:

Q: What relationship does Prof. Peter Vowden have with Tissue Therapies?